Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2012

01.09.2012 | short review

Advanced neuroimaging techniques for diagnosis and treatment evaluation in neuro-oncology

verfasst von: Bernhard Schuknecht, MD, Krisztina Baráth, MD, Silvia Hofer, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Novel therapies of central nervous system (CNS) malignancies have evoked the demand to increasingly integrate dedicated imaging techniques into the diagnostic work-up and treatment evaluation in neuro-oncology. In primary and secondary malignancies of the CNS, advanced neuroimaging techniques enable non-invasive assessment of tissue microstructure, cellular and vascular proliferation and capillary permeability. Furthermore, eloquent cortical areas in the vicinity of tumours and the course of white matter pathways are rendered visible to facilitate surgical therapy.
The armamentarium of magnetic resonance (MR) imaging techniques includes diffusion-weighted imaging (DWI), perfusion-weighted imaging (PWI), diffusion-tensor imaging (DTI), functional MRI (f-MRI) and MR spectroscopy (MRS). Computed tomography perfusion (perfusion CT) may serve as an alternative to magnetic resonance perfusion (perfusion MR). These new imaging techniques lend support to distinguish the primary brain neoplasms from the secondary brain neoplasms, aid in grading of gliomas, delineate infiltration beyond visible boundaries on contrast-enhanced images and thus support guidance for biopsies and surgical resection. Surveillance and treatment monitoring of neoplasms may shift from almost exclusive reliance on contrast enhancement to an imaging approach that combines traditional morphology with advanced “functional” techniques.
Validation of these new developments is ongoing based on the observations in clinical neuro-oncology, radiation oncology, histopathology and neurosurgery. Application of advanced imaging protocols may promise to improve diagnosis, to stratify patients to an increasing diversity of treatment options and potentially individualise therapy.
Fußnoten
1
Figure legends (same patient in Figs. 1, 2, 3, 4, 5 and 6) exemplifying preoperative assessment of a patient with mixed oligodendroglioma.
 
Literatur
1.
Zurück zum Zitat Hofer S, Lassmann AB. Molecular markers in gliomas: impact for the clinician. Target Oncol. 2010;5:201–10.PubMedCrossRef Hofer S, Lassmann AB. Molecular markers in gliomas: impact for the clinician. Target Oncol. 2010;5:201–10.PubMedCrossRef
2.
Zurück zum Zitat Tabatabai G, Stupp R, Van Den Bent MJ, et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. (2010) 120:585–92.PubMedCrossRef Tabatabai G, Stupp R, Van Den Bent MJ, et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. (2010) 120:585–92.PubMedCrossRef
3.
Zurück zum Zitat Carillo JA, Lai A, Nghiemphu PL. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012. doi:10.3174/ajnr.A2950. Carillo JA, Lai A, Nghiemphu PL. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012. doi:10.3174/ajnr.A2950.
4.
Zurück zum Zitat Kim JW, Park CK, Park SH, et al. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry. 2011;82:224–7.PubMedCrossRef Kim JW, Park CK, Park SH, et al. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry. 2011;82:224–7.PubMedCrossRef
5.
Zurück zum Zitat Goze C, Rigau V, Gibert L, et al. Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? J Neurooncol. 2009;91:1–5.PubMedCrossRef Goze C, Rigau V, Gibert L, et al. Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? J Neurooncol. 2009;91:1–5.PubMedCrossRef
6.
Zurück zum Zitat Drabycz S, Roldan G, de Robles P, et al. An analysis of image texture, tumorlocation, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2010;49:1398–405.PubMedCrossRef Drabycz S, Roldan G, de Robles P, et al. An analysis of image texture, tumorlocation, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2010;49:1398–405.PubMedCrossRef
7.
Zurück zum Zitat Wen P, Macdonald DR, Reardon DAR, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72PubMedCrossRef Wen P, Macdonald DR, Reardon DAR, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72PubMedCrossRef
8.
Zurück zum Zitat Ellingson BM, Mark G, Malkin MG, Rand SD, et al. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol. 2011;102:95–103. Ellingson BM, Mark G, Malkin MG, Rand SD, et al. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol. 2011;102:95–103.
9.
Zurück zum Zitat Arvinda HR, Kesavadas C, Sarma PS, et al. Glioma grading:sensitivity, specificity, positive and negative predictive values of diff usion and perfusion imaging. J Neurooncol. 2009;94:87–96.PubMedCrossRef Arvinda HR, Kesavadas C, Sarma PS, et al. Glioma grading:sensitivity, specificity, positive and negative predictive values of diff usion and perfusion imaging. J Neurooncol. 2009;94:87–96.PubMedCrossRef
10.
Zurück zum Zitat Gupta A, Young RJ, Karimi S, et al. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol. 2011;32:1301–6.PubMedCrossRef Gupta A, Young RJ, Karimi S, et al. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol. 2011;32:1301–6.PubMedCrossRef
11.
Zurück zum Zitat Chiang IC, Kuo Y-T, Luc-Y, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imaging. Neuroradiology. 2004;46:619–27. Chiang IC, Kuo Y-T, Luc-Y, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imaging. Neuroradiology. 2004;46:619–27.
12.
Zurück zum Zitat Barajas RF Jr., Rubenstein JL, Chang JS, et al. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2010;31:60–6. Barajas RF Jr., Rubenstein JL, Chang JS, et al. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2010;31:60–6.
13.
Zurück zum Zitat Pope WB, Kim HJ, Huo J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252:182–9.PubMedCrossRef Pope WB, Kim HJ, Huo J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252:182–9.PubMedCrossRef
14.
Zurück zum Zitat Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion maps an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26:3387–94.PubMedCrossRef Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion maps an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26:3387–94.PubMedCrossRef
15.
Zurück zum Zitat Pope WB, Lai A, Mehta R, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011; 32:882–9.PubMedCrossRef Pope WB, Lai A, Mehta R, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011; 32:882–9.PubMedCrossRef
16.
Zurück zum Zitat Mong S, Ellingson BM, Nghiemphu PL, et al. Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol. 2012. doi:10.3174/ajnr.A3053. Mong S, Ellingson BM, Nghiemphu PL, et al. Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol. 2012. doi:10.3174/ajnr.A3053.
17.
Zurück zum Zitat Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume andvascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004; 25: 746–5.PubMed Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume andvascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004; 25: 746–5.PubMed
18.
Zurück zum Zitat Law M, Oh S, Babb JS, et al. Low grade gliomas: dynamic susceptibility weighted contrast enhanced perfusion MR imaging prediction of patient clinical response. Radiology. 2006; 238:658–67.PubMedCrossRef Law M, Oh S, Babb JS, et al. Low grade gliomas: dynamic susceptibility weighted contrast enhanced perfusion MR imaging prediction of patient clinical response. Radiology. 2006; 238:658–67.PubMedCrossRef
19.
Zurück zum Zitat Maia ACM, Malheiros SMF, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol. 2005;26:777–83.PubMed Maia ACM, Malheiros SMF, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol. 2005;26:777–83.PubMed
20.
Zurück zum Zitat Tykocinski ES, Grant RA, Kapoor GS, et al. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro-Oncol. 2012;14:613–23.PubMedCrossRef Tykocinski ES, Grant RA, Kapoor GS, et al. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro-Oncol. 2012;14:613–23.PubMedCrossRef
21.
Zurück zum Zitat Essig M, Anzalone N, Combs SE, et al. MR Imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR Am J Neuroradiol. 2012;33:803–17.PubMedCrossRef Essig M, Anzalone N, Combs SE, et al. MR Imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR Am J Neuroradiol. 2012;33:803–17.PubMedCrossRef
22.
Zurück zum Zitat Haldorsen IS, Espeland A, Larsson E.-M, et al. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol. 2011;32:984–92.PubMedCrossRef Haldorsen IS, Espeland A, Larsson E.-M, et al. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol. 2011;32:984–92.PubMedCrossRef
23.
Zurück zum Zitat Danchaivijitr N, Waldman AD, Tozer DJ, et al. Low grade gliomas: do changes in rCBV measurements at longitudinal perfusion weighted MR imaging predict malignant transformation? Radiology. 2008;247:170–8.PubMedCrossRef Danchaivijitr N, Waldman AD, Tozer DJ, et al. Low grade gliomas: do changes in rCBV measurements at longitudinal perfusion weighted MR imaging predict malignant transformation? Radiology. 2008;247:170–8.PubMedCrossRef
24.
Zurück zum Zitat Tsien C, Galbán CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010;28:2293–9.PubMedCrossRef Tsien C, Galbán CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010;28:2293–9.PubMedCrossRef
25.
Zurück zum Zitat Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging—pilot study. Radiology, 2010;255:622–8.PubMedCrossRef Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging—pilot study. Radiology, 2010;255:622–8.PubMedCrossRef
26.
Zurück zum Zitat Mangla R, Singh G, Ziegelitz D, et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology. 2010;256:575–84.PubMedCrossRef Mangla R, Singh G, Ziegelitz D, et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology. 2010;256:575–84.PubMedCrossRef
27.
Zurück zum Zitat Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. 2008;30:552–8.PubMedCrossRef Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. 2008;30:552–8.PubMedCrossRef
28.
Zurück zum Zitat Kong D-S, Kim ST, Kim E-H, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and lxygen-6-Methylguanine-DNA Methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382–7.PubMedCrossRef Kong D-S, Kim ST, Kim E-H, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and lxygen-6-Methylguanine-DNA Methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382–7.PubMedCrossRef
29.
Zurück zum Zitat Stadlbauer A, Ganslandt O, Buslei R, et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology. 2006;240:803–10.PubMedCrossRef Stadlbauer A, Ganslandt O, Buslei R, et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology. 2006;240:803–10.PubMedCrossRef
30.
Zurück zum Zitat Inoue T, Ogasawara K, Beppu T, et al. Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas. Clin Neurol Neurosurg. 2005;107:174–80.PubMedCrossRef Inoue T, Ogasawara K, Beppu T, et al. Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas. Clin Neurol Neurosurg. 2005;107:174–80.PubMedCrossRef
31.
Zurück zum Zitat Price SJ Jena R, Burnet NG, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor Imaging: an image-guided biopsy study. AJNR Am J Neuroradiol. 2006;27:1969–74.PubMed Price SJ Jena R, Burnet NG, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor Imaging: an image-guided biopsy study. AJNR Am J Neuroradiol. 2006;27:1969–74.PubMed
32.
Zurück zum Zitat Price SJ, Jena R, Burnet NG, et al. Predicting patterns of glioma recurrence using diffusion tensor imaging. Eur Radiol. 2007;17:1675–87.PubMedCrossRef Price SJ, Jena R, Burnet NG, et al. Predicting patterns of glioma recurrence using diffusion tensor imaging. Eur Radiol. 2007;17:1675–87.PubMedCrossRef
33.
Zurück zum Zitat Saksena S, Jain R, Narang J, et al. Predicting survival in glioblastomas using diffusion tensor imaging metrics. J Magn Reson Imaging. 2010;32:788–95.PubMedCrossRef Saksena S, Jain R, Narang J, et al. Predicting survival in glioblastomas using diffusion tensor imaging metrics. J Magn Reson Imaging. 2010;32:788–95.PubMedCrossRef
34.
Zurück zum Zitat Sundgren PC, Fan X, Weybright P, et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast enhancing lesions. Magn Reson Imaging. 2006;24:1131–42.PubMedCrossRef Sundgren PC, Fan X, Weybright P, et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast enhancing lesions. Magn Reson Imaging. 2006;24:1131–42.PubMedCrossRef
35.
Zurück zum Zitat Bello L, Gambini A, Castellano A, et al. Motor and language DTI fiber tracking combined with intraoperative subcortical mapping for surgical removal of gliomas. NeuroImage. 2008;39:369–82.PubMedCrossRef Bello L, Gambini A, Castellano A, et al. Motor and language DTI fiber tracking combined with intraoperative subcortical mapping for surgical removal of gliomas. NeuroImage. 2008;39:369–82.PubMedCrossRef
36.
Zurück zum Zitat Partovi S, Jacobi B, Rapps N, et al. Clinical standardized fMRI reveals altered language lateralization in brain tumor patients. AJNR Am J Neuroradiol. doi:10.3174/ajnr.A3137. Partovi S, Jacobi B, Rapps N, et al. Clinical standardized fMRI reveals altered language lateralization in brain tumor patients. AJNR Am J Neuroradiol. doi:10.3174/ajnr.A3137.
37.
Zurück zum Zitat Roux FE, Boulanouar K, Ibarrola D, et al. Functional MRI and intraoperative brain mapping to evaluate brain plasticity in patients with brain tumours and hemiparesis. J Neurol Neurosurg Psychiatry. 2000;69(4):453–63. Roux FE, Boulanouar K, Ibarrola D, et al. Functional MRI and intraoperative brain mapping to evaluate brain plasticity in patients with brain tumours and hemiparesis. J Neurol Neurosurg Psychiatry. 2000;69(4):453–63.
38.
Zurück zum Zitat Desmurget M, Bonnetblanc F, Duffau H. Contrasting acute and slow-growing lesions: a new door to brain plasticity. Brain. 2007, 130, 898–914.PubMedCrossRef Desmurget M, Bonnetblanc F, Duffau H. Contrasting acute and slow-growing lesions: a new door to brain plasticity. Brain. 2007, 130, 898–914.PubMedCrossRef
39.
Zurück zum Zitat Roessler K, Donat M, Lanzenberger R, et al. Evaluation of preoperative high magnetic field motor functional MRI (3 Tesla) in glioma patients by navigated electrocortical stimulation and postoperative outcome. J Neurol Neurosurg Psychiatry. 2005;76:1152–7.PubMedCrossRef Roessler K, Donat M, Lanzenberger R, et al. Evaluation of preoperative high magnetic field motor functional MRI (3 Tesla) in glioma patients by navigated electrocortical stimulation and postoperative outcome. J Neurol Neurosurg Psychiatry. 2005;76:1152–7.PubMedCrossRef
40.
Zurück zum Zitat Hattingen E, Delic O, Franz K, et al. 1H MRSI and progression-free survival in patients with WHO grades II and III gliomas. Neurol Res. 2010; 32: 593–602.PubMedCrossRef Hattingen E, Delic O, Franz K, et al. 1H MRSI and progression-free survival in patients with WHO grades II and III gliomas. Neurol Res. 2010; 32: 593–602.PubMedCrossRef
41.
Zurück zum Zitat Law M, Yang, S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989–98.PubMed Law M, Yang, S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989–98.PubMed
42.
Zurück zum Zitat Elias A, Carlos RC, Smith E, et al. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Acad Radiol. 2011;18:1101–8.PubMedCrossRef Elias A, Carlos RC, Smith E, et al. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Acad Radiol. 2011;18:1101–8.PubMedCrossRef
43.
Zurück zum Zitat Balmaceda C, Critchell D, Mao X, et al. Multisection 1H magnetic resonancespectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol. 2006;76:185–91.PubMedCrossRef Balmaceda C, Critchell D, Mao X, et al. Multisection 1H magnetic resonancespectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol. 2006;76:185–91.PubMedCrossRef
44.
45.
Zurück zum Zitat Zeng QS, Li CF, Zhang K, et al. Multivoxel 3D proton MR spectroscopy inthe distinction of recurrent glioma from radiation injury. J Neurooncol. 2007;84:63–9.PubMedCrossRef Zeng QS, Li CF, Zhang K, et al. Multivoxel 3D proton MR spectroscopy inthe distinction of recurrent glioma from radiation injury. J Neurooncol. 2007;84:63–9.PubMedCrossRef
46.
Zurück zum Zitat Jeon JY, Kovanlikaya I, Boockvar JA, et al. Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton magnetic resonance spectroscopic imaging study. AJNR Am J Neuroradiol. 2012 May 10. doi:0.3174/ajnr.A3091. Jeon JY, Kovanlikaya I, Boockvar JA, et al. Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton magnetic resonance spectroscopic imaging study. AJNR Am J Neuroradiol. 2012 May 10. doi:0.3174/ajnr.A3091.
Metadaten
Titel
Advanced neuroimaging techniques for diagnosis and treatment evaluation in neuro-oncology
verfasst von
Bernhard Schuknecht, MD
Krisztina Baráth, MD
Silvia Hofer, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0046-8

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012 Zur Ausgabe